Literature DB >> 24165176

Are vancomycin trough concentrations adequate for optimal dosing?

Michael N Neely1, Gilmer Youn, Brenda Jones, Roger W Jelliffe, George L Drusano, Keith A Rodvold, Thomas P Lodise.   

Abstract

The current vancomycin therapeutic guidelines recommend the use of only trough concentrations to manage the dosing of adults with Staphylococcus aureus infections. Both vancomycin efficacy and toxicity are likely to be related to the area under the plasma concentration-time curve (AUC). We assembled richly sampled vancomycin pharmacokinetic data from three studies comprising 47 adults with various levels of renal function. With Pmetrics, the nonparametric population modeling package for R, we compared AUCs estimated from models derived from trough-only and peak-trough depleted versions of the full data set and characterized the relationship between the vancomycin trough concentration and AUC. The trough-only and peak-trough depleted data sets underestimated the true AUCs compared to the full model by a mean (95% confidence interval) of 23% (11 to 33%; P = 0.0001) and 14% (7 to 19%; P < 0.0001), respectively. In contrast, using the full model as a Bayesian prior with trough-only data allowed 97% (93 to 102%; P = 0.23) accurate AUC estimation. On the basis of 5,000 profiles simulated from the full model, among adults with normal renal function and a therapeutic AUC of ≥400 mg · h/liter for an organism for which the vancomycin MIC is 1 mg/liter, approximately 60% are expected to have a trough concentration below the suggested minimum target of 15 mg/liter for serious infections, which could result in needlessly increased doses and a risk of toxicity. Our data indicate that adjustment of vancomycin doses on the basis of trough concentrations without a Bayesian tool results in poor achievement of maximally safe and effective drug exposures in plasma and that many adults can have an adequate vancomycin AUC with a trough concentration of <15 mg/liter.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24165176      PMCID: PMC3910745          DOI: 10.1128/AAC.01653-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  A Bayesian approach to tracking patients having changing pharmacokinetic parameters.

Authors:  David S Bayard; Roger W Jelliffe
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-02       Impact factor: 2.745

3.  Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.

Authors:  Adam Frymoyer; B Joseph Guglielmo; Adam L Hersh
Journal:  Pediatr Infect Dis J       Date:  2013-10       Impact factor: 2.129

4.  Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire.

Authors:  C M Tobin; J M Darville; A H Thomson; G Sweeney; J F Wilson; A P MacGowan; L O White
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

5.  Survey of vancomycin monitoring guidelines in Illinois hospitals.

Authors:  W E Fitzsimmons; M J Postelnick; P V Tortorice
Journal:  Drug Intell Clin Pharm       Date:  1988 Jul-Aug

6.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

7.  Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies.

Authors:  K A Rodvold; J C Rotschafer; S S Gilliland; D R Guay; K Vance-Bryan
Journal:  Ther Drug Monit       Date:  1994-02       Impact factor: 3.681

8.  Optimal sampling times for pharmacokinetic experiments.

Authors:  D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1981-12

9.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Vancomycin pharmacokinetics in patients with various degrees of renal function.

Authors:  K A Rodvold; R A Blum; J H Fischer; H Z Zokufa; J C Rotschafer; K B Crossley; L J Riff
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more
  103 in total

1.  Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?

Authors:  Karisma Patel; Ashley S Crumby; Holly D Maples
Journal:  Paediatr Drugs       Date:  2015-04       Impact factor: 3.022

2.  Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.

Authors:  Kimberly C Claeys; Evan J Zasowski; Anthony M Casapao; Abdalhamid M Lagnf; Jerod L Nagel; Cynthia T Nguyen; Jessica A Hallesy; Mathew T Compton; Keith S Kaye; Donald P Levine; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 3.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

4.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Authors:  Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

6.  Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: A pilot study.

Authors:  D M Martirosov; M R Bidell; M P Pai; M H Scheetz; S L Rosenkranz; T P Lodise
Journal:  Diagn Microbiol Infect Dis       Date:  2017-04-02       Impact factor: 2.803

7.  Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.

Authors:  Doaa M Aljefri; Sean N Avedissian; Nathaniel J Rhodes; Michael J Postelnick; Kevin Nguyen; Marc H Scheetz
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

8.  Pharmacokinetic Assessment of Pre- and Post-Oxygenator Vancomycin Concentrations in Extracorporeal Membrane Oxygenation: A Prospective Observational Study.

Authors:  Ahmed A Mahmoud; Sean N Avedissian; Abbas Al-Qamari; Tiffany Bohling; Michelle Pham; Marc H Scheetz
Journal:  Clin Pharmacokinet       Date:  2020-12       Impact factor: 6.447

Review 9.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

10.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.